Significant correlation seen between lifestyle and both cognitive function and Aβ42/40 ratio
THURSDAY, June 13, 2024 (HealthDay News) — For patients with mild cognitive impairment (MCI) or early dementia due to Alzheimer disease (AD), comprehensive lifestyle changes may improve cognition and function, according to a study published online June 7 in Alzheimer”s Research & Therapy.
Dean Ornish, M.D., from Preventive Medicine Research Institute in Sausalito, California, and colleagues conducted a randomized controlled phase 2 trial involving 51 individuals aged 45 to 90 years with MCI or early dementia due to AD and a Montreal Cognitive Assessment score of 18 or higher. Changes in cognition and function tests were examined after 20 weeks of an intensive multidomain lifestyle intervention versus a wait-list usual-care control group.
The researchers found significant between-group differences in the Clinical Global Impression of Change (CGIC), Clinical Dementia Rating-Sum of Boxes (CDR-SB), and Clinical Dementia Rating Global (CDR Global), as well as borderline significant differences in the Alzheimer”s Disease Assessment Scale (ADAS-Cog) after 20 weeks. Compared with the control group, which worsened in all four measures, the intervention group showed improvement in cognition and function on the CGIC, CDR-Global, and ADAS-Cog and showed significantly less progression on the CDR-SB. There was an increase in the β-amyloid (Aβ)42/40 ratio in the intervention group and a decrease in the control group. A significant correlation was seen between lifestyle and both cognitive function and the plasma Aβ42/40 ratio. Improvement in the microbiome was only seen in the intervention group.
“These findings support longer follow-up and larger clinical trials to determine the longer-term outcomes of this intensive lifestyle medicine intervention in larger groups of more diverse AD populations,” the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
NOACs Linked to Slower Cognitive Decline in Patients With A-Fib, Alzheimer Disease
Cortical Atrophy in Early-Onset Alzheimer Disease Signature Can Predict Progression to Dementia
Exercise Link to Dementia Varies by Physical Activity Domain
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Gene Mutation Identified That Increases Lung Cancer Risk
Distinct Skin Microbiome Features Emerge Before Atopic Disease Onset in Infants
Therapies Compared for Newly Diagnosed Multiple Sclerosis
Initial Rx Length Tied to Long-Term Use of Z-Drugs